Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen

Transplant Infectious Disease

Volumn 12, Issue 5, 2010, Pages 412-420

  Shigematsu, A ^a,b   Yamamoto, S ^a,b   Sugita, J ^a,b   Kondo, T ^a,b   Onozawa, M ^a,b   Kahata, K ^a,b   Endo, T ^a,b   Shiratori, S ^a,b   Ota, S ^a,b   Yamaguchi, K ^a,b   Wakasa, K ^a,b   Takahata, M ^a,b   Goto, H ^a,b   Ito, S ^a,b   Takemura, R ^a,b   Tanaka, J ^a,b   Hashino, S ^a,b   Nishio, M ^a,b   Koike, T ^a   Asaka, M ^a   Imamura, M ^a,b   more..

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bacterial infection; Bone marrow transplantation; Febrile neutropenia; Graft versus host disease; Reduced intensity conditioning

Indexed keywords

BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; BONE MARROW TRANSPLANTATION; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; BONE MARROW TRANSPLANTATION; CATHETERIZATION, CENTRAL VENOUS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650496835     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00560.x     Document Type: Article

References (29)

1. Serody JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am 1997; 11: 459-477.
2. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
3. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
4. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512-525.
5. Hori A, Kami M, Kim SW, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 65-72.
6. Frère P, Baron F, Bonnet C, et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 2006; 37: 411-418.
7. Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004; 6: 171-178.
8. Busca A, Locatelli F, Barbui A, et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003; 5: 132-139.
9. Daly A, McAfee S, Dey B, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9: 373-382.
10. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-255.
11. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177.
12. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
13. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
14. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
15. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9-15.
16. Bjorklund A, Aschan J, Labopin M, et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 40: 1055-1062.
17. Engels EA, Ellis CA, Supran SE, et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 1999; 28: 256-266.
18. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients given methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328-1332.
19. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
20. Narimatsu H, Miyakoshi S, Yamaguchi T, et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. Biol Blood Marrow Transplant 2005; 11: 429-436.
21. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, CE1-7. MMWR Recomm Rep 2000; 49 (RR-10): 1-125.
22. Takahata M, Hashino S, Okada K, et al. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients. Am J Hematol 2010; 85: 243-248.
23. Shigematsu A, Kondo T, Yamamoto S, et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2008; 14: 568-575.
24. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004; 39 (Suppl 1): S49-S52.
25. O'Grady NP, Alexander M, Dellinger EP, et al. Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002; 23: 759-769.
26. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
27. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
28. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
29. Morishima Y, Kodera Y, Hirabayashi N, et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A, B, DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 1995; 15: 235-239.